Pharmaceutical Technology

APRIL 6, 2023

The Singapore Health Sciences Authority (HSA) has accepted Everest Medicines’ new drug application (NDA) for Nefecon to treat adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. Singapore has therefore become the second country to accept the NDA, following mainland China in November 2022.

Food and Drug Administration 52

Food and Drug Administration Food Medicine Safety 52

Pharma Marketing Network

MARCH 23, 2023

The Food and Drug Administration (FDA) has recently approved a new drug for the treatment of Alzheimer’s disease called Leqembi. This approval marks a major milestone in the fight against Alzheimer’s, which is the sixth leading cause of death in the United States and affects over 5 million people.

Food and Drug Administration 52

Food and Drug Administration FDA Consulting Food 52

European Pharmaceutical Review

JANUARY 3, 2023

Talquetamab is an investigational, off-the-shelf treatment targeting both GPRC5D, a novel drug target that is on some normal cells but overexpressed on myeloma cells, and CD3 on t-cells. The first Phase II results from the study were presented at the 2022 American Society of Hematology (ASH) Annual Meeting.

Marketing 78

Marketing Food and Drug Administration Medicine Food 78

European Pharmaceutical Review

JANUARY 4, 2024

Immunotherapy drugs like teclistamab can result in potentially fatal side effects, including CRS and immune cell-associated neurotoxicity syndrome (ICANS). The drug tocilizumab for example, has been used historically to treat CRS from immunotherapies. An overactive immune response [is] the hallmark of CRS,” Landgren added.

Side effects 74

Side effects Food and Drug Administration Patients Medicine 74

Pharmaceutical Technology

APRIL 19, 2023

While the Clarksville, US-based company completed a Phase Ia study in healthy participants to eventually develop the drug for Alzheimer’s disease, it is likely that the company will now focus on Parkinson’s disease in its Phase II study first, said Kelleher-Andersson. Similarly, research collaborations are also a consideration.

Food and Drug Administration 52

Food and Drug Administration Recruitment Prospecting Food 52

Pharmaceutical Technology

MAY 23, 2023

In 2022, Avrobio’s investigational gene therapy, AVR-RD-04, received a rare paediatric disease designation from the US Food and Drug Administration. The company will also provide knowledge transfer and other related services to support the programme’s transition.

Food and Drug Administration 103

Food and Drug Administration Food Leads Pharmaceutical 103

PM360

AUGUST 9, 2022

EPA Administrator Michael Regan said the agency will take more aggressive action against PFAS. People on the front-lines of PFAS contamination have suffered for far too long,” EPA Administrator Michael Regan said in a statement. Drug Approvals. DC Dispatch: PFAS Are More Harmful Than Originally Stated. FDA Update.

Healthcare 52

Healthcare Healthcare Food and Drug Administration FDA 52

European Pharmaceutical Review

JULY 13, 2023

3 With established drug development pathways, we are accustomed to a rigid structure of translation from bench to bedside. It is estimated that only one in 10 drugs that enter Phase I trials are subsequently licensed by the US Food and Drug Administration (FDA). This could lead to significant research waste.

Medical 82

Medical Food and Drug Administration Pharmacology Medicine 82

Pharmaceutical Technology

MAY 12, 2023

Last month, the US Food and Drug Administration (FDA) granted the treatment an orphan drug designation for sickle cell disease. In December 2022, the company presented data from the first two patients treated in the Phase I/II RUBY (NCT04853576) trial.

Food and Drug Administration 98

Food and Drug Administration Food Safety Patients 98

European Pharmaceutical Review

MARCH 6, 2023

Harwell, the UK’s leading science and innovation campus in Oxfordshire will be the location of the Moderna Innovation and Technology Centre (MITC). This milestone follows the finalisation of Moderna’s ten-year strategic partnership with the UK government, announced in December 2022.

Manufacturing 80

Manufacturing Food and Drug Administration Government Food 80

European Pharmaceutical Review

JUNE 29, 2023

Based on scientific knowledge and process understanding, manufacturers of drugs and drug substances have a broad awareness of potential impurities – including nitrosamine impurities – that could form during manufacturing or degradation. 1 Nitrosamines are not new or unknown impurities.

Food and Drug Administration 83

Food and Drug Administration Manufacturing Food Medicine 83

Contrarian Sales Techniques

DECEMBER 14, 2022

The biotechnology and drug sectors performed well in the second half of 2022 after struggling in the first six months. Despite the uncertainty surrounding the global economy, the drug and biotechnology sectors have continued to perform well in the second half of 2022.

Food and Drug Administration 52

Food and Drug Administration Pharmaceutical Sales Medicine 52

European Pharmaceutical Review

JANUARY 29, 2024

1 Some five years after the initial NDMA (N-nitrosodimethylamine) contamination issue 2 initially affecting valsartan drug substance, then other active pharmaceutical ingredients (APIs), eg, sartans, ranitidine, metformin, etc; the toxic short alkyl chain N-nitrosamine issue appears, if not resolved, then well on the way to resolution.

Pharmaceutical 94

Pharmaceutical Food and Drug Administration Medicine FDA 94

Pharmaceutical Technology

JUNE 5, 2023

Led by the investment company Temasek, the round will also be used to improve the company’s commercial readiness as its lead radiopharmaceutical candidate ITM-11 is being studied in Phase III trials in gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Other investors included BlackRock, the Qatar Investment Authority, and Nextech.

Food and Drug Administration 59

Food and Drug Administration Food Manufacturing Patients 59

pharmaphorum

NOVEMBER 2, 2022

The most common solutions today for pain relief are non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, meaning that standard treatments have not changed for a number of years. This leads to psychological harm becoming a significant factor in chronic pain, alongside the physical symptoms. The potential for a digital solution.

Food and Drug Administration 131

Food and Drug Administration Food FDA Patients 131

Pharmaceutical Technology

APRIL 27, 2023

Pompe Disease, also known as glycogen storage type II, is a rare inherited lysosomal disorder caused by a deficiency of enzyme acid alpha-glucosidase (GAA) leading to the accumulation of glycogen in skeletal and cardiac muscles. Sanofi markets avalglucosidase alfa as Lumizyme in the US to treat LOPD since its approval in 2010.

Food and Drug Administration 52

Food and Drug Administration Food Marketing Medicine 52

Pharmaceutical Technology

JUNE 12, 2023

Patients with erectile dysfunction (ED) will now be able to access a topical treatment without the need for a prescription after the US Food and Drug Administration (FDA) greenlit Futura Medical’s Eroxon. Both drugs have generic equivalents available and are PDE5 inhibitors that can take 30 to 60 minutes to kick in.

Food and Drug Administration 52

Food and Drug Administration FDA Prescription Food 52

Pharmaceutical Technology

MAY 16, 2023

Food and Drug Administration (FDA) for the prevention of typhoid fever, and the only FDA-licensed vaccine for the prevention of cholera caused by Vibrio cholerae serogroup O1. Following the completion of the deal, Bavarian Nordic now boasts the only oral vaccine licensed by the U.S.

Food and Drug Administration 52

Food and Drug Administration FDA Manufacturing Food 52

European Pharmaceutical Review

SEPTEMBER 29, 2022

The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) through the Office of Pharmaceutical Quality in 2021 embarked on an initiative to develop a framework for establishing a pharmaceutical manufacturing site quality rating system, the Quality management maturity (QMM) programme.

Management 74

Management Food and Drug Administration Manufacturing Pharmaceutical manufacturing 74

pharmaphorum

JANUARY 23, 2023

Beijing-based pharma, BeiGene’s Brukinsa (zanubrutinib) has been approved by the US Food and Drug Administration (FDA) for chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). CLL is a common form of leukaemia and accounts for roughly 25% of all new cases each year. of patients.

FDA 52

FDA Food and Drug Administration Food Patients 52

European Pharmaceutical Review

NOVEMBER 4, 2022

Nevertheless, chemotherapy’s disadvantages, including substantial toxicities, combined with inconvenient hospital-based intravenous (IV) administration, impede patients’ ability to stay on treatment and their quality of life. tumour effects. The importance of taxanes in oncology.

Food and Drug Administration 79

Food and Drug Administration FDA Pharmaceutical Patients 79

Legacy MEDSearch

JANUARY 31, 2023

Food and Drug Administration has approved the company’s fourth-generation rechargeable sacral neuromodulation system. The Axonics R20 neurostimulator utilizes the same small 5cc form factor as the Axonics R15 and is paired with the same tined lead and intuitive patient remote control. Axonics, Inc., 1 ranking in 2021.

FDA 98

FDA Food and Drug Administration Recruitment Medical 98

European Pharmaceutical Review

AUGUST 10, 2022

It was approved by the US Food and Drug Administration in October 2021 as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis, specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (the two main forms of ANCA-associated vasculitis), in combination with standard therapy.

Food and Drug Administration 74

Food and Drug Administration Pharmaceutical Food Medical 74

Legacy MEDSearch

FEBRUARY 13, 2023

Food and Drug Administration (FDA) 510(k) clearance and launch of the company’s upgraded AI-powered software. We are committed to continuous improvement to optimize the clinical utility of the Swoop® system while driving commercial adoption across leading institutions globally. Hyperfine, Inc., Hyperfine, Inc.

Food and Drug Administration 98

Food and Drug Administration FDA Recruitment Food 98

European Pharmaceutical Review

DECEMBER 22, 2022

The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category” The term ‘mRNA’ has become commonplace globally. The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category.

Medicine 102

Medicine Food and Drug Administration Transportation Distribution 102

pharmaphorum

JUNE 27, 2022

Jennifer Mathieu, director of government relations at the Academy of Managed Care Pharmacy (AMCP), tells us why the organisation backed the pre-approval information exchange (PIE) Act of 2022 and how the legislation will empower companies to share information with healthcare payers and plans during the FDA approval process. .

Food and Drug Administration 77

Food and Drug Administration Medical Patients FDA 77

European Pharmaceutical Review

JUNE 27, 2023

difficile in December 2022, the microbiome therapies space in 2023 has continued to see revolutionary developments and continued research advancement. This followed results from a large metagenomics study published in November 2022, in which gut microbiome was identified as a key part of Parkinson’s pathogenesis.

Food and Drug Administration 96

Food and Drug Administration Manufacturing Medicine Pharma 96

European Pharmaceutical Review

MAY 29, 2023

Recently, the European Medicines Agency (EMA) took the lead in pushing for process improvements using technologies already established in other manufacturing sectors. Despite this, only 13 nanomedicines had been approved by the US Food and Drug Administration (FDA) before 2015. Tanzini et al.

Food and Drug Administration 69

Food and Drug Administration Manufacturing Pharma Pharmaceutical 69

Pharmaceutical Technology

APRIL 4, 2023

While Scorpion will lead the development of STX-721, Pierre Fabre will handle STX-241. The Boston, Massachusetts-based Scorpion expects to submit an investigational new drug (IND) application for STX-721 to the US Food and Drug Administration (FDA) in mid-2023, with an IND application for STX-241 expected in H1 2024.

Food and Drug Administration 52

Food and Drug Administration Biopharma FDA Pharmaceutical 52

Legacy MEDSearch

MARCH 15, 2023

In February 2022, HeartBeam partnered with LIVMOR to build a HeartBeam-branded version of LIVMOR’s FDA-cleared Halo cloud-based software platform to connect physicians and patients. HeartBeam AIMI and HeartBeam AIMIGo have not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies.

Food and Drug Administration 97

Food and Drug Administration FDA Recruitment Physicians 97

PM360

MARCH 22, 2024

Amor Vegas stated, “T cells have the ability to develop memory and persist in your body for really long periods, which is very different from a chemical drug. and is one of the leading causes of kidney failure. Car T cells can help slow down aging by attacking senescent cells that multiply with age but don’t die off.

Food and Drug Administration 52

Food and Drug Administration FDA Healthcare Healthcare 52

European Pharmaceutical Review

MAY 4, 2023

Martin Vogel, Janssen’s Therapeutic Area Lead Oncology for the Europe, Middle-East and Africa (EMEA) region shared with EPR what makes the BsMAb promising for treating this indication. Why are bispecific monoclonal antibody drugs such as amivantamab promising for this indication? 2022; 10(1). 2022; 24(2): 89 – 97.

Food and Drug Administration 89

Food and Drug Administration Safety Medicine Patients 89

European Pharmaceutical Review

FEBRUARY 15, 2023

Neoadjuvant nivolumab did not lead to surgical delays. Neoadjuvant nivolumab in combination with chemotherapy was approved by the US Food and Drug Administration (FDA) in March 2022 for lung cancer. Only one late-onset immune-related adverse event (AE) occurred, 16 months post-treatment.

Food and Drug Administration 84

Food and Drug Administration Patients Food Networking 84

European Pharmaceutical Review

MARCH 7, 2024

Last month, construction began on Europe’s first industrial-scale facility dedicated to the production of lead-212 based radioligand therapies. billion between 2022 to 2027. Based on these promising results, the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to AlphaMedix in February 2024.

Manufacturing 52

Manufacturing Food and Drug Administration Marketing Management 52

Nixon Gwilt Law

DECEMBER 16, 2021

What can Healthcare and Life Sciences businesses and investors anticipate for the healthcare industry in 2022? What do you think will be the biggest surprise of 2022? Anything else you'd like to share about 2022 predictions and trends? And now you get the benefit of all that experience as we lay out what to look for in 2022.

Healthcare 52

Healthcare Healthcare Food and Drug Administration Ethics 52

Pharmaceutical Technology

JUNE 8, 2023

While the company previously shared interim biomarker and safety data from the Phase I/II AEROW trial (NCT05248230) in November 2022, the update features further results detailing the drug’s effects on quality-of-life and spirometry-measured outcomes in a limited set of patients. 4DMT presented the results on 8 June at 5pm CET.

Patients 98

Patients Food and Drug Administration Food Safety 98

European Pharmaceutical Review

AUGUST 31, 2023

In addition, radionuclide therapy has the potential to achieve high efficacy rates since the administered drugs spare surrounding healthy tissue, thus, reducing the burden on the patient. 1-4 Besides these drug products, several companies worldwide are developing radiotheranostics in clinical trials built on various radionuclides.

Food and Drug Administration 75

Food and Drug Administration Manufacturing Safety Transportation 75